RIVN, LCID, MU, NVO, TSLA: Top 5 Trending Stocks Today - Lucid Gr (NASDAQ:LCID), Micron Technology (NASDA

　　On Tuesday, U.S. stocks showed mixed results. The Dow Jones Industrial Average closed down by nearly 0.8%, finishing at 39,112.16. The S&P 500 rose by almost 0.4% to end the regular session at 5,469.30, while the Nasdaq climbed nearly 1.3% to close at 17,717.65.

　　These are the top stocks that gained the attention of retail traders and investors throughout the day:

　　Rivian Automotive IncRIVN

　　Rivian shares surged 8.63% to close at $11.96 after reports of Volkswagens plan to invest $5 billion into the company as part of an electric vehicle joint venture. The German automaker is set to invest $1 billion immediately and pump an additional $4 billion over time. The joint venture will focus on developing next-generation battery-powered vehicles.

　　Lucid Group IncLCID

　　Lucid Group shares traded lower by 2.34% to close at $2.50 on Tuesday. The company announced the appointment of Nick Tworkas head of Global Communications, who will oversee Lucid's global communications team and report directly to Lucid CEO Peter Rawlinson.

　　Micron Technology IncMU

　　Micron Technology shares rose by 1.52% to close at $141.12. Rosenblatt analyst Hans Mosesmannmaintained Micron as a Buy with a $225 price target, expecting the company to deliver a beat-and-raise as it enters one of the most significant memory cycles in history.

　　Novo NordiskNVO

　　Novo Nordisk shares moved higher by 3.25% to close at $146.91 following China's approval of Novo's weight loss drug, Wegovy. China, the second most populated country, is estimated to have the world's highest number of overweight individuals. Read more here.

　　Tesla IncTSLA

　　Tesla shares increased by 2.61% to close at $187.35. Emil Michael, former chief business officer at Uber Technologies, recently expressed skepticism about the financial feasibility of robotaxis, citing the high cost of production.

　　Photo by WHYFRAME on Shutterstock

　　This story was generated using Benzinga Neuro and edited by Shivdeep Dhaliwal

　　© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.